Shire buys US drugs delivery firm for pounds 105m
Wednesday 26 February 1997
The news came as Core Group, a company specialising in sustained release drug delivery products, announced that its pounds 73m stock market flotation had been "heavily oversubscribed" at 250p a share.
To part finance the Pharmavene deal and other acquisitions being contemplated, Shire is raising pounds 11.5m by way of a one-for-10 placing and offer at 214p a share. The group is also understood to be in negotiations for the purchase of an unnamed company in Europe and a product range in the UK for total of pounds 14m.
Despite the flood of new equity, the share price dropped just 3.5p to 234p yesterday as analysts welcomed the deal and news of lower-than-expected losses of pounds 105,000 in the latest six months. Dr Rolf Stahel, Shire's chief executive, said it had effectively achieved break-even in six months, rather than the 12 months forecast by the market.
Pharmavene gives Shire another 11 potential new products, taking the pipeline to 30. The US group has created a high-throughput method of screening how well particular drug formulations penetrate human cells in the laboratory. It is applying the results in 11 projects to develop technologies for the delivery and release of drugs more effectively into the body.
The lead product is Carbatrol, a controlled release form of carbamazepine, a drug used in the treatment of epilepsy. Carbatrol, which is licensed to Athena, part of the Irish drugs delivery group Elan, could be launched later this year. If successful, it would compete directly with Novartis' Tegretol drug, which had sales of $340m in 1994.
Another product under development is a more efficient version of Glaxo Wellcome's Zovirax anti-herpes drug. But the bigger potential could come from an oral form of Calcitonin, used for the treatment of brittle bones, which could attack a world market currently put at $5bn.
Separately, Oxford Molecular, a biotechnology group, announced that it was investing pounds 500,000 in Cambridge Combinatorial, a new drug research company run by Allan Marchington, the brother of Oxford's chief executive Tony Marchington.
Oxford will take a 20 per cent stake in Cambridge. The new company plans to use combinatorial chemistry to supply potential drug prospects to other drug and biotech groups. It claims it will have an edge on similar companies by providing a narrower range of compounds for screening as new drug prospects.
- 1 Unseen Charlie and the Chocolate Factory chapter deemed 'too subversive' released
- 2 Ebola virus: It's ripped through towns – now the deadliest ever outbreak of the virus is heading for Africa's teeming cities
- 3 Joan Rivers: 'Palestinians deserve to be dead'
- 4 A teacher speaks out: 'I'm effectively being forced out of a career that I wanted to love'
- 5 Mexican woman becomes world’s 'oldest person' at 127
Israel-Gaza crisis: YouTube footage shows scale of destruction after 50 days of shelling
Keira Knightley topless: Conservative actress does own take on #Freethenipple campaign for Interview Magazine
iPhone 6 'hidden code' could indicate sharper screens or bigger phones
Joan Rivers: 'Palestinians deserve to be dead'
Ebola virus: It's ripped through towns – now the deadliest ever outbreak of the virus is heading for Africa's teeming cities
Robin Williams Emmys tribute led by Billy Crystal criticised for including 'racist' joke about Muslim woman
Rotherham child sex abuse scandal: Labour Home Office to be probed over what Tony Blair's government knew - and when
The Rotherham child abuse scandal is a tale of apologists, misogyny and double standards
What do immigrants really think of Britain? Polish immigrant's Reddit post goes viral
Do you realise just how foolish the UK looks?
With Douglas Carswell joining Ukip, my party has taken another giant step forward
- < Previous
- Next >
iJobs Money & Business
£18000 - £23000 per annum + Commission: SThree: Real Staffing are currently lo...
£40000 - £70000 per annum + Bonus+Benefits+Package: Harrington Starr: C# .NET ...
£40000 - £70000 per annum + benefits+bonus+package: Harrington Starr: Data Ana...
Highly Attractive Salary: Austen Lloyd: BRISTOL - This is a very unusual law c...